Drug information provided by: Merative, Micromedex®
Venetoclax is used alone or together with other medicines (eg, rituximab) to treat chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, in patients who have received at least one previous treatment. It is also used together with obinutuzumab to treat previously untreated CLL or SLL.
Venetoclax is also used together with other medicines (eg, azacitidine, decitabine, low-dose cytarabine) to treat newly-diagnosed acute myeloid leukemia (AML) in adults 75 years of age and older or who have other medical conditions that prevent the use of standard chemotherapy.
Venetoclax is an antineoplastic agent (cancer medicine). It interferes with the growth of cancer cells, which are eventually destroyed by the body.
This medicine is available only with your doctor's prescription.
This product is available in the following dosage forms:
Portions of this document last updated: Sept. 01, 2023
لا تُقدم Mayo Clinic الدعم للشركات أو المنتجات المُعلَّن عنها هنا. لكن تدعم العائدات الإعلانية رسالتنا غير الربحية.
تحقق من هذه الكتب الأكثر مبيعًا والعروض الخاصة على الكتب والنشرات الإخبارية من Mayo Clinic Press.
تساهم التبرّعات، وهي قابلة للخصم الضريبي، في دعم آخر التطورات في الأبحاث وطرق الرعاية لإحداث نقلة نوعية في الطب.